NO has been reported to participate in tumor progression and cancer metastasis, and some studies showed the potential of NOS inhibitors for anticancer therapies [24], such as the studies about triple-negative breast cancer [25] and colorectal cancer [26]. The gene discussed is NOS2; the disease is triple-negative breast carcinoma.